Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
KDR inferred haplotype is associated with upper limb dysfunction in breast cancer survivors of mixed ancestry.
|
31118800 |
2019 |
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
It was found that both rare homozygotes in the ANLN:rs12535394 and KDR:rs11133360 SNP pair are prognostic of favorable breast cancer survival and underpin the prominent roles of the immune response in cancer state control.
|
31578580 |
2019 |
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We evaluated dietary factors associated with oxidative balance, DDIT4 (one SNP), FLT1 (35 SNPs), HIF1A (four SNPs), KDR (19 SNPs), MPO (one SNP), NOS2A (15 SNPs), TEK (40 SNPs) and VEGFA (eight SNPs) and breast cancer risk among Hispanic (2,111 cases and 2,597 controls) and non-Hispanic white (1,481 cases and 1,586 controls) women in the Breast Cancer Health Disparities Study.
|
23832257 |
2014 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Vascular endothelial growth factor receptor 2 (VEGFR2) mediated calcineurin/nuclear factor of activated T-cells (NFAT) pathway is crucial in the angiogenesis of human breast cancer.
|
27041643 |
2016 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
An induction of apoptosis and a decrease in cell migration, accompanied by transduction inhibition of Raf-1/MAPK/ERK pathway, were observed in MCF-7 cells after treatment with II-9OH, suggesting that II-9OH is a promising candidate for the development of multifunctional agents targeting ERα and VEGFR-2 in the therapy of some breast cancers.
|
29587221 |
2018 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate concentrations, diagnostic utility and power of VEGF-A, VEGF-C, VEGF-D and VEGFR-2 in comparison to CA15-3 in breast cancer (BC) patients.
|
30387014 |
2019 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Kit, a tyrosine kinase growth factor receptor, and its ligand, stem cell factor (SCF), are commonly coexpressed in breast cancer.
|
10634512 |
1999 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Successful treatment with a combination of anti-VEGFR2 and anti-PD-L1 antibodies induced high endothelial venules (HEVs) in PyMT (polyoma middle T oncoprotein) breast cancer and RT2-PNET (Rip1-Tag2 pancreatic neuroendocrine tumors), but not in glioblastoma (GBM).
|
28404866 |
2017 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, in vitro studies of the VEGFR-2 inhibition in human breast cancer MCF-7 cell line for the promising cytotoxic compounds showed that compounds 7a, 8c, 9b, 9c and 9d were potent inhibitors at low micromolar concentrations (IC<sub>50</sub> = 0.034-0.582 μM) compared to the reference drug, sorafenib (IC<sub>50</sub> = 0.019 μM).
|
30641320 |
2019 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Fluorescence in situ hybridization (FISH) was used to quantify gene copy numbers of VEGFR2 and KIT in 83 primary human breast cancers including 31 TNBCs.
|
22170730 |
2012 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Above results proved that, by attenuating the pro-angiogenic communication through VEGFR2, ICJ is a novel angiogenic inhibitor and will be a promising supplement for anti-angiogenic chemotherapy for breast cancer.
|
29403376 |
2017 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
In particular, we found that one novel combination, pairing the estrogen response modifier raloxifene with the c-Met/VEGFR2 kinase inhibitor cabozantinib, dramatically potentiated the drugs' individual antitumor effects in a mouse model of breast cancer.
|
27879272 |
2017 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
To analyze the efficacy and tolerability of cabozantinib-a small molecule inhibitor of MET and VEGFR2-alone or with trastuzumab in patients with breast cancer brain metastases (BCBM).
|
31541381 |
2020 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
All these results together with molecular modeling studies open a new avenue for the development of multifunctional agents targeting ERα and VEGFR-2 in the therapy of some breast cancers.
|
28942113 |
2017 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Receptors with intrinsic kinase activity such as EGFR and VEGFR directly or indirectly induce STAT3 activation in various breast cancer types.
|
26559373 |
2016 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pharmaceutically targeting VEGFR-2 by isomangiferin could be an effective therapeutic strategy for breast cancer.
|
29628979 |
2018 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Most of the tested compounds showed potent preferential inhibition effects against human VEGFR-2 and remarkable anticancer activities in the human breast cancer cell line MCF-7.
|
28787092 |
2017 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases.
|
23071298 |
2012 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
CTD_human |
Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up.
|
20135347 |
2010 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Also, negative correlations between circulating EPCs and histological grading as well as a soluble form of VEGFR2 with histological grading of breast cancer according to the Elston-Ellis classification were observed.
|
30818220 |
2019 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
In vivo monitoring of angiogenesis inhibition via down-regulation of mir-21 in a VEGFR2-luc murine breast cancer model using bioluminescent imaging.
|
23951172 |
2013 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
This demonstrates that breast cancer can interact with the sensory nervous system to drive neuritogenesis through a VEGF-A/VEGFR2/ARP2/3 mediated pathway.
|
29100335 |
2017 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Apatinib, an inhibitor of vascular endothelial growth factor receptor-2, has been shown to promote anti-cancer action across a wide range of malignancies, including gastric, lung, and breast cancers.
|
30301881 |
2018 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
While vascular endothelial growth factor (VEGF) expression in breast tumors has been correlated with a poor outcome in the pathogenesis of breast cancer, the expression, localization, and function of VEGF receptors VEGFR1 (also known as FLT1) and VEGFR2 (also known as KDR or FLK1), as well as neuropilin 1 (NRP1), in breast cancer are controversial.
|
17550303 |
2007 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interestingly, exposure of rMCF-7 cells or PMA-treated sMCF-7 cells to the specific inhibitors of VEGFR-2 and VEGFR-3 reduces markedly the tubular network formation.
|
22542663 |
2012 |